NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis $0.33 -0.03 (-8.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.34 +0.01 (+2.73%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioAtla Stock (NASDAQ:BCAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioAtla alerts:Sign Up Key Stats Today's Range$0.33▼$0.3650-Day Range$0.33▼$0.5252-Week Range$0.24▼$2.53Volume492,189 shsAverage Volume791,629 shsMarket Capitalization$19.28 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California. Read More BioAtla Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreBCAB MarketRank™: BioAtla scored higher than 41% of companies evaluated by MarketBeat, and ranked 656th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingBioAtla has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioAtla has received no research coverage in the past 90 days.Read more about BioAtla's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($1.46) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioAtla's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.27% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in BioAtla has recently increased by 2.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.27% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in BioAtla has recently increased by 2.91%, indicating that investor sentiment is decreasing. News and Social Media2.2 / 5News SentimentN/A News SentimentBioAtla has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by Insiders11.50% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioAtla's insider trading history. Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAB Stock News HeadlinesBioAtla Stock Short Interest Report | NASDAQ:BCAB - BenzingaJuly 29, 2025 | benzinga.comBioAtla, Inc. (BCAB) latest stock news and headlines - Yahoo FinanceJuly 18, 2025 | uk.finance.yahoo.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 2 at 2:00 AM | Brownstone Research (Ad)BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia MeetingJuly 17, 2025 | globenewswire.comBioAtla Reports Encouraging Preliminary Results from Phase 1 Study of BA3182 in Heavily Pretreated Metastatic Adenocarcinoma Patients - NasdaqJuly 5, 2025 | nasdaq.comBioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers CongressJuly 3, 2025 | globenewswire.comBCAB - BioAtla Inc Ordinary Shares Ownership - MorningstarJuly 1, 2025 | morningstar.comMBioAtla Approves 2025 Corporate Bonus PlanJune 20, 2025 | tipranks.comSee More Headlines BCAB Stock Analysis - Frequently Asked Questions How have BCAB shares performed this year? BioAtla's stock was trading at $0.5912 at the beginning of 2025. Since then, BCAB shares have decreased by 44.2% and is now trading at $0.33. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.01. Read the conference call transcript. When did BioAtla IPO? BioAtla (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioAtla own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings5/06/2025Today8/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAB CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for BioAtla$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+1,415.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.78 million Net MarginsN/A Pretax Margin-562.51% Return on Equity-373.47% Return on Assets-116.55% Debt Debt-to-Equity RatioN/A Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$11 million Price / Sales1.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book1.32Miscellaneous Outstanding Shares58,420,000Free Float51,700,000Market Cap$19.28 million OptionableOptionable Beta0.90 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:BCAB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.